The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: Should biological therapy be suspended?;Aparecimento de psoríase durante o tratamento das doenças inflamatórias intestinais com infliximabe: A terapia biológica deve ser suspensa?

Arquivos de Gastroenterologia

Volumn 49, Issue 2, 2012, Pages 172-176

  Denadai, Rafael ^a   Teixeira, Fábio Vieira ^a   Saad Hossne, Rogério ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Biological therapy; Inflammatory bowel disease; Infliximab; Psoriasis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

ACANTHOSIS; BIBLIOGRAPHIC DATABASE; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EMBASE; ENTERITIS; EPITHELIUM HYPERPLASIA; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; MEDLINE; PARAKERATOSIS; PHOTOTHERAPY; PHYSICIAN; PLASMACYTOID DENDRITIC CELL; PSORIASIS; PSORIASIS VULGARIS; REMISSION; REVIEW; SKIN BIOPSY; SPONDYLARTHRITIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PSORIASIS;

EID: 84863796295     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032012000200014     Document Type: Review

References (45)

1. Adams DR, Buckel T, Sceppa JA. Infliximab associated new-onset psoriasis. J Drugs Dermatol. 2006;5:178-9.
2. Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis. 2007;13:1059-61.
3. Ávila-Alvarez A, García-Alonso L, Solar-Boga A, García-Silva J. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An Pediatr (Barc). 2009;70:278-81.
4. Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165:1109-17.
5. Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol. 2007;34:380-5.
6. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40.
7. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001.
8. Conklin LS, Cohen B, Wilson L, Cuffari C, Oliva-Hemker M. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:174-7.
9. Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, Ramos-Polo E, Santos-Juanes J. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis. 2008;14:1462-3.
10. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318-27.
11. Doyle LA, Sperling LC, Baksh S, Lackey J, Thomas B, Vleugels RA, Qureshi AA, Velazquez EF. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-aatherapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol. 2011;33:161-6.
12. English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J Cutan Med Surg. 2009;13:40-2.
13. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Asscge G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8.
14. Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921-7.
15. Goldstein J, Levine J. Infliximab-induced psoriaform rash. Clin Gastroenterol Hepatol. 2010;8:A24.
16. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:230-2.
17. Iborra M, Beltrán B, Bastida G, Aguas M, Nos P. Infliximab and adalimumabinduced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis. 2011;5:157-61.
18. Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol. 2010;32:568-73.
19. Lindgren S, Groth O. Generalized pustular psoriasis. A report on thirteen patients. Acta Derm Venereol. 1976;56:139-47.
20. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Bio Drugs. 2010;24 Suppl 1:3-14.
21. Manni E, Barachini P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int J Immunopathol Pharmacol. 2009;22:841-4.
22. Medkour F, Babai S, Chanteloup E, Buffard V, Delchier JC, Le-Louet H. Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab. Gastroenterol Clin Biol. 2010;34:140-1.
23. Papadavid E, Gazi S, Dalamaga M, Stavrianeas N, Ntelis V. Palmoplantar and scalp psoriasis occurring during antitumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol. 2008;22:380-2.
24. Parian A, Scherl EJ, Kumar S, Taunk R, Green N, Lakehomer H, et al. Risk of developing anti-TNF alpha induced psoriasis among patients with Crohn's disease: are all anti-TNFS equal? Gastroenterology, 2010;138 Suppl 1:S672.
25. Park BC, Lim HJ, Kim BS, Lee WJ, Kim do W, Lee SJ. Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease. Ann Dermatol. 2009;21:60-2.
26. Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology. 2007;215:295-300.
27. Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol. 2005;30:713-4.
28. Pérez-Pérez L, Caeiro JL, Fabeiro JM, Allegue F, Zulaica A. Induction of pustular lesions during infliximab therapy for Crohn's disease. Acta Derm Venereol. 2008;88:292-3.
29. Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2011 Oct 13. [Epub ahead of print] doi: 10.1111/j.1525-1470.2011.01521.x.
30. Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology. 2006;213:182-6.
31. Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol. 2010;27:539-40.
32. Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A, Laharie D, Reimund JM, Lémann M, Delaporte E, Colombel JF; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-55.
33. Richetta A, Mattozzi C, Carlomagno V, Maiani E, Carboni V, Giancristoforo S, D'Epiro S, Bruni F, Calvieri S. A case of infliximab-induced psoriasis. Dermatol Online J. 2008;14(11):9.
34. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161:1081-8.
35. Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis. 2007;80:231-7.
36. Sherlock ME, Walters TD, Zachos M, Muise A, Griffiths AM. Infliximab-induced psoriasis in pediatric Crohn disease; experience of this paradoxical skin manifestation at a tertiary centre and a potential association with a variation in the IL-23r gene. Gastroenterology. 2009;136 Suppl 1:A671.
37. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-ppinhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2011 Jul 11. [Epub ahead of print] doi: 10.1016/j.jaad.2011.05.038.
38. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007;34:468-72.
39. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3:439-40.
40. Tichy M, Tichy M, Kopova R, Sternbersky J, Ditrichova D. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease. J Dermatolog Treat. 2011 Jan 22. [Epub ahead of print] doi: 10.3109/09546634.2010.521811.
41. Umeno J, Matsumoto T, Jo Y, Ichikawa M, Urabe K, Iida M. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2007;13:1188-9.
42. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54-7.
43. Wermuth J, Kind F, Steuerwald M. Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn's sacroiliitis. Clin Gastroenterol Hepatol. 2009;7:A28.
44. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1-14.
45. Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther. 2010;31:553-60.